Last €44.03 EUR
Change Today +2.47 / 5.93%
Volume 475.0
EII On Other Exchanges
As of 3:21 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (EII) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - €44.03
52 Week Low
02/6/14 - €26.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (EII)

Related News

No related news articles were found.

eisai co ltd (EII) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (EII) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (EII) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (EII) Key Developments

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in the Philippines

Eisai Co., Ltd. and Ajinomoto Pharmaceuticals Co., Ltd. announced that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. Ajinomoto Pharmaceuticals holds the manufacturing and marketing authorization rights to LIVAMIN Oral Granules. Under a basic contract concerning the marketing rights of LIVAMIN Oral Granules in the Asia region signed in February 2009, Eisai obtained the exclusive marketing rights from Ajinomoto Pharmaceuticals to distribute the product in the Philippines as well as Hong Kong, China and Macao. In April 2014, Eisai's subsidiary HI-Eisai Pharmaceutical Inc. received approval in the Philippines for LIVAMIN Oral Granules indicated for the improvement of hypoalbuminemia in patients with decompensated hepatic cirrhosis presenting with hypoalbuminemia despite adequate dietary intake. In hepatic cirrhosis, increase of fibrous tissues in the liver as chronic hepatitis progresses leads to hardening of the liver and results in loss of normal liver function. When hepatic cirrhosis is not accompanied with clearly defined symptoms despite partial damage to liver function, it is called compensated cirrhosis. When liver function worsens and presents with symptoms such as jaundice, malaise, ascites, edema, hepatic encephalopathy, it is called decompensated cirrhosis. The cause of such symptoms associated with decompensated hepatic cirrhosis includes malnutrition or metabolic disorder resulting from hypoalbuminemia that occurs as hepatic cirrhosis progresses. LIVAMIN Oral Granules ameliorates these symptoms by increasing serum albumin levels in patients with decompensated hepatic cirrhosis. Liver cirrhosis is a serious health issue in the Philippines, with around 127,000 people estimated to have liver cirrhosis and in 2010, it is said that approximately 9,200 people died due to liver cirrhosis.

Eisai Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Eisai Co., Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Eisai Co., Ltd. Receives Approval of a New Indication for Proton Pump Inhibitor Pariet® Tablets 10 mg in Japan

Eisai Co., Ltd. announced that it has received approval of a new indication for proton pump inhibitor Pariet® Tablets 10 mg (rabeprazole sodium, “Pariet”) in Japan for use in the prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy. In addition, Eisai has also received approval of a 5 mg tablet formulation with the same indication as Pariet Tablets 10 mg. The data used in the application was from a Phase II/III study (Study 308 /Study 309) on patients who required long-term administration of low-dose aspirin and who were confirmed to also have a history of gastric or duodenal ulcers. The results of Study 308 showed that cumulative recurrence rates of gastric or duodenal ulcers over 24 weeks (the study's primary endpoint) in the 5 mg and 10 mg Pariet groups were 2.8% and 1.4%, respectively, compared to 21.7% for the comparator group (teprenone). Thus, both Pariet groups demonstrated a significantly better preventative effect than the comparator group (p<0.001 for both Pariet groups vs. the comparator group) 1 . Furthermore, in Study 309 which examined the long term administration of Pariet 5 mg and 10 mg for a maximum of 52 weeks after initial treatment of 24 weeks, both dosage groups maintained a preventative effect over the whole 76 week maximum treatment period. The most commonly reported side effects (5 or more cases observed) in both Study 308 and 309 were diarrhea and constipation, and this was consistent with the known safety profile of Pariet. In addition, the registration validity period for this indication for Pariet is 4 years. By gaining this approval, Eisai aims to increase the clinical value of the drug so as to further contribute to the range of treatment options available to patients with acid-related diseases.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EII:GR €44.03 EUR +2.47

EII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €15.47 EUR +0.05
Nektar Therapeutics $14.64 USD -0.42
Salix Pharmaceuticals Ltd $134.67 USD -0.47
Santen Pharmaceutical Co Ltd ¥7,360 JPY +130.00
Synergy Health PLC 2,165 GBp -10.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EII Industry Range
Price/Earnings 99.2x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 103.0x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at